Reprise: Gemtuzumab Ozogamicin for Older Patients With Acute Myeloid Leukemia
Cet article analyse les travaux récents sur le gemtuzumab ozogamicine pour le traitement de patients âgés atteints d'une leucémie myéloïde aiguë
The article by Burnett et al published with this editorial again focuses our attention on the use of gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody linked to a calicheamicin derivative, as a component of therapy for older adults who have been diagnosed with acute myeloid leukemia (AML). The authors report that in a prospective randomized trial, a single dose of GO at the beginning of induction chemotherapy was associated with clinically meaningful and statistically significant improvement in the cumulative incidence of relapse, relapse-free survival, and overall survival. This study sends a strong message about choice of end points and study design in trials of newagents inAML,and adds positive evidence to the mixed collection of clinical results for this intriguing drug....
Journal of Clinical Oncology , éditorial en libre accès, 2012